Skip to main content

Prior Head Injury Linked to Amyloid Deposition

SAN DIEGO — Patients with a history of head injury show significant increases in amyloid deposition in key parts of the brain, including the frontal cortex, a finding that further supports evidence linking head injury with dementia later in life.
"Our study found associations between prior head injury and increased amyloid deposition both globally and within the frontal cortex, including orbitofrontal, prefrontal, and superior frontal cortices," Andrea Schneider, MD, PhD, from Johns Hopkins University, Baltimore, Maryland, told Medscape Medical News.
"Our findings suggest that the frontal cortex may be particularly susceptible to the damaging effects of head injury."
The findings were presented here at the ANA 2017: 48th Annual Meeting of the American Neurological Association.
Head injury has been linked to dementia in previous epidemiologic studies, and while the mechanisms are not well understood, amyloid and tau depositions are speculated to be likely factors.
To take a closer look at the association, Dr Schneider and her colleagues identified 329 participants in the Atherosclerosis Risk and Communities (ARIC) study who underwent positron emission tomography assessing brain amyloid deposition between 2011 and 2013.
The patients had a mean age of 76 years, 57% were female, 43% were black, and 20% had a history of head injury, defined by self-report or hospitalization International Classification of Diseases, Ninth Revision, codes. Approximately one third (27%) of patients had mild cognitive impairment; however, patients with dementia were excluded.
Dr Schneider noted that patients with head injuries had sustained the injuries a mean of approximately 25 years earlier.
Those with a history of head injury showed elevated (greater than 1.2) standard uptake value ratios (SUVRs) indicating the presence of amyloid deposition, in global assessments (prevalence ratio [PR], 1.31; 95% confidence interval [CI], 1.07 - 1.60).
The elevated levels were specifically in the orbitofrontal cortex (PR, 1.24; 95% CI, 1.02 - 1.50), the prefrontal cortex (PR, 1.24; 95% CI, 1.03 - 1.49), and the superior frontal cortex (PR, 1.29; 95% CI, 1.06 - 1.56).
Meanwhile, there were no significant differences in the prevalence of elevated SUVR in the anterior cingulate, posterior cingulate, precuneus, lateral temporal, parietal, or occipital lobes (all P > .05).
"It was exciting to see that the frontal cortex was particularly associated with increased amyloid deposition among those with prior head injury," Dr Schneider said.
"We had also hypothesized that the posterior cingulate and precuneus areas would have elevated amyloid deposition, as these areas, along with the frontal cortex, have been shown to have early amyloid deposition in Alzheimer's dementia — but this hypothesis was not validated in our sample."
The findings add to ongoing speculation of a link between traumatic brain injury (TBI) and Alzheimer's disease, Dr Schneider added.
"Overall, our study is consistent with the conclusion that there is some overlap in areas with amyloid deposition in TBI and in early Alzheimer's pathology," she said.
Additional research is needed to better understand how amyloid deposition with head injury relates to dementia, Dr Schneider noted.
"Further work is needed to determine if this increased amyloid deposition contributes to dementia and cognitive decline following head injury in this population — this is an area of active research within the ARIC cohort study."

Insight on Mechanism

The study offers important insights on the possible mechanisms that could explain how TBI and amyloid relate, said Ramon Diaz-Arrastia, MD, PhD, presidential professor of neurology and attending neurologist at the Penn Presbyterian Medical Center Hospital of the University of Pennsylvania, in Philadelphia.

"It's been known for a long time that TBI, particularly more moderate or severe injury, is associated with an increased risk of dementia — approximately two- or threefold or so," he told Medscape Medical News.
"But little is known about the mechanism, and there is some [speculation] that TBI accelerates Alzheimer's disease pathology, and another view is that it accelerates perhaps another type of pathology, such as tau-related pathology or vascular dementia," he explained.
"So I think this is an important study because it is among the few that have looked at amyloid deposition in people with a history with TBI."
The location of the amyloid disposition that was identified "is also intriguing in that it is different from that expected with Alzheimer's disease," Dr Diaz-Arrastia said.
"The increased amyloid deposition is not in the canonical Alzheimer's disease regions but rather in these areas in the frontal lobes, which is important because the indications are that the features of dementia in people with TBI are not exactly like those we see with Alzheimer's disease."
The authors and Dr Diaz-Arrastia have disclosed no relevant financial relationships.
ANA 2017: 48th Annual Meeting of the American Neurological Association. Abstract M336WIP. Presented October 16, 2017.

Comments

Popular posts from this blog

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Sitting at Work Raises All-Cause and CV Mortality Risk

May 21, 2012 (Lyon, France) — Sitting at work raises the risk of dying from cardiovascular (CV) and metabolic diseases, as well as the risk of dying from all causes, regardless of any exercise in which the individual may engage. That was the finding of a study reported here at the 19th European Congress on Obesity (ECO) by Anne Grunseit, PhD, from the Prevention Research Collaboration in the School of Public Health at the University of Sydney, Australia, and Norwegian colleagues. Research is increasingly focusing on sedentary behavior with low energy expenditure, including sitting and lying down, as behavioral risk factors for obesity and chronic disease. Sitting occurs during travel, while watching television, using computers, and reading. But with people often spending at least 9 hours a day at work, with fewer than 20% of jobs requiring physical exertion, and with many people spending at least 4 hours a day sitting at work, the sedentary time at work is high, and many people ar...